Citryll is a Targeting Neutrophil Extracellular Traps
Citryll has raised €119M across 3 funding rounds from 9 investors, most recently a Series B round in Dec 2024. Based in Oss, Netherlands; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors |
|---|
| 2024-12-10 | Series B | €85M | BioGeneration Ventures,BOM,Citryll’s founders,Curie Capital,Forbion,Johnson & Johnson+3 more | View deal → |
| 2020-02-07 | Other | €19M | BioGeneration Ventures,Seventure Partners | View deal → |
| 2019-07-01 | Series A | €15M | — | View deal → |
